Investigating new treatment pathways for a deadly liver cancer
Exploring novel SRC-regulated pathways in IDH mutant intrahepatic cholangiocarcinoma
This study is looking at a type of liver cancer called intrahepatic cholangiocarcinoma and is testing a new approach to treatment that uses a drug called dasatinib for patients whose tumors have certain genetic changes, hoping to find better options than standard chemotherapy.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Fred Hutchinson Cancer Center NIH-funded |
| Lab location | 1 site (Seattle, United States) |
| Project ID | NIH-11044148 on NIH RePORTER |
What this research studies
This research focuses on intrahepatic cholangiocarcinoma (ICC), a severe form of liver cancer that is becoming more common and has a poor prognosis. The study aims to identify targeted therapies for patients with specific genetic mutations in their tumors, particularly those involving the IDH gene. By using laboratory models, the researchers have found that a drug called dasatinib can effectively kill cancer cells with these mutations. The goal is to shift treatment from traditional chemotherapy to more effective targeted therapies that could improve patient outcomes.
Who could benefit from this research
Good fit: Ideal candidates for this research are patients diagnosed with intrahepatic cholangiocarcinoma who have mutations in the IDH gene.
Not a fit: Patients with intrahepatic cholangiocarcinoma who do not have IDH mutations may not benefit from this targeted therapy approach.
Why it matters
Potential benefit: If successful, this research could lead to more effective and less toxic treatment options for patients with IDH mutant intrahepatic cholangiocarcinoma.
How similar studies have performed: Other research has shown promising results with targeted therapies for similar genetic mutations in various cancers, indicating potential for success in this approach.
Where this research is happening
Seattle, United States
- Fred Hutchinson Cancer Center — Seattle, United States (Active)
Researchers
- Principal investigator: Kugel, Sita — Fred Hutchinson Cancer Center
- Study coordinator: Kugel, Sita
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.